BioAge Labs Stock Plummets Nearly 60% on Negative Read-Through From Novo Nordisk Trial

Shares of BioAge Labs (BIOA) plummeted in morning trading, falling by as much as 59.6%, after a major clinical trial failure by Novo Nordisk raised fundamental questions about the viability of BioAge's lead drug candidate.

Novo Nordisk Trial Misses Primary Endpoint

The selloff was triggered by an announcement from Novo Nordisk that its Phase 3 ZEUS trial for ziltivekimab failed to meet its primary endpoint. The trial, which enrolled over 6,300 patients, did not show a statistically significant reduction in the risk of major adverse cardiovascular events compared to a placebo.

According to the results, ziltivekimab, an IL-6 pathway inhibitor, posted a hazard ratio of 0.99. This indicates it was no more effective than the placebo in preventing heart attacks and strokes in high-risk patients with cardiovascular disease, chronic kidney disease, and elevated inflammation.

Implications for BioAge's Pipeline

The ZEUS trial's failure has a direct negative read-through for BioAge because it casts doubt on the entire cardiovascular inflammation hypothesis. This is the scientific basis for BioAge's own lead asset, BGE-102, an oral NLRP3 inhibitor being evaluated in a Phase 2 trial for patients with obesity and systemic inflammation.

Ad

Critically, while ziltivekimab successfully suppressed the inflammatory biomarker hsCRP in the ZEUS trial, this did not translate into clinical benefit. BioAge had previously reported that BGE-102 also achieved significant reductions in hsCRP in Phase 1 studies, which it had positioned as a key value driver. The Novo Nordisk result suggests that lowering this biomarker may not be sufficient to improve cardiovascular outcomes, increasing the perceived risk for BioAge's program.

Broader Market Impact

The sharp decline in BioAge's stock reflects a rapid recalibration by investors of the probability of success for the entire class of cardiovascular inflammation therapies. The news also dragged down shares of other companies with exposure to this space, such as Monte Rosa Therapeutics.

The selloff occurred amid a slightly negative tone in the broader market, with the S&P 500 and Dow Jones Industrial Average posting modest declines. However, the magnitude of BioAge's drop was driven almost entirely by the specific clinical trial news and its direct scientific overlap with the company's pipeline.